Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma

Journal of Drugs in Dermatology

Volumn 14, Issue 3, 2015, Pages 219-221

  Alcalay, Joseph ^a,b   Tauber, Gil ^c   Fenig, Eyal ^c   Hodak, Emmilia ^c  

^a ASSUTA MEDICAL CENTER   (Israel)

^b ARIEL UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CASE REPORT; CHEMOSURGERY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FULL THICKNESS SKIN GRAFT; HUMAN; MALE; POSTOPERATIVE PERIOD; TREATMENT DURATION; ADJUVANT THERAPY; CARCINOMA, BASAL CELL; FEMALE; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MOHS SURGERY; NEOADJUVANT THERAPY; PYRIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84924727155     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Rubin AI, Chen EH, and Ratner D. Basal-cell carcinoma. N Engl J Med. 2005; 353: 2262-2269.
2. Weiss GJ and Korn RL. Metastatic basal cell carcinoma in the era of Hedgehog signaling pathway inhibitors. Cancer. 2012; 118: 5310-5319.
3. Bayers S, Kapp DL, Beer KR, Slavin B. Treatment of margin positive basal cell carcinoma with Vismodegib: case report and consideration of treatment options and their implications. J Drugs Dermatol. 2013; 12:s147-s150.
4. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366: 2171-2179.
5. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366: 2180-2188.
6. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, Vismodegib. J Am Acad Dermatol. 2014; 70:60-69.
7. Maier T, Kulichova D, Ruzicka T, Berking C. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: Pseudocysts as a sign of tumor regression. J Am Acad Dermatol. 2014; 71:725-730.
8. Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, Oro A, Kim J, Chang AL, Tang JY. An investigator-initiated open-label clinical trial of Vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Jun 11. S0190-9622.